Zehra Tuğçe GÜR MAZ, Sümeyye TURANLI, H. Burak CALISKAN

POTANSİYEL FAAH İNHİBİTÖRÜ OLARAK BAZI ARİLHİDRAZON TÜREVİ BİLEŞİKLERİN TASARIMI VE SENTEZİ

Amaç: FAAH enziminin inhibisyonu amacıyla bir seri arilhidrazon türevi bileşiğin tasarımı, sentezi ve enzim aktif bölgesinde olası etkileşimlerinin incelenmesidir.

Anahtar Kelimeler:

Arilhidrazonlar, FAAH, heterosiklikler, inflamasyon

DESIGN AND SYNTHESIS OF SOME ARYLHYDRAZONE DERIVATIVES AS POTENTIAL FAAH INHIBITORS

Objective: The aim was to design, synthesis and investigation of possible interactions in the enzyme active site of a series of arylhydrazone derivatives for the inhibition of the FAAH enzyme.”

Keywords:

Arylhydrazones, FAAH, heterocycles, inflammation,

PDF

___

1. Van Egmond, N., Straub, V.M., van der Stelt, M. (2021). Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors. Annual Review of Pharmacology and Toxicology, 61, 441-463. [CrossRef]
2. Mechoulam, R., Parker, L. A. (2013). The Endocannabinoid System and the Annual Review of Psychology, 64(1), 21-47. [CrossRef]
3. Lutz, B., Marsicano, G., Maldonado, R., Hillard, C.J. (2015). The endocannabinoid system in guarding against fear, anxiety and stress. Nature Reviews Neuroscience, 16(12), 705-718. [CrossRef]
4. Tuo, W., Leleu-Chavain, N., Spencer, J., Sansook, S., Millet, R., Chavatte, P. (2017). Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors. Journal of Medicinal Chemistry, 60(1), 4-46. [CrossRef]
5. Sachs, J., McGlade, E., Yurgelun-Todd, D. (2015). Safety and Toxicology of Cannabinoids. Neurotherapeutics, 12(4), 735-746. [CrossRef]
6. Bajaj, S., Jain, S., Vyas, P., Bawa, S., Vohora, D. (2021). The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? Brain Research Bulletin, 174, 305-322. [CrossRef]
7. Bonifácio, M.J., Sousa, F., Aires, C., Loureiro, A.I., Fernandes-Lopes, C., Pires, N.M., Palma, P.N., Moser, P., Soares-da-Silva, P. (2020). Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10-2474. British Journal of Pharmacology, 177(9), 2123-2142. [CrossRef]
8. Ahn, K., Smith, S.E., Liimatta, M.B., Beidler, D., Sadagopan, N., Dudley, D.T., Young, T., Wren, P., Zhang, Y., Swaney, S., Van Becelaere, K., Blankman, J.L., Nomura, D.K., Bhattachar, S.N., Stiff, C., Nomanbhoy, T.K., Weerapana, E., Johnson, D.S., Cravatt, B.F. (2011). Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. The Journal of Pharmacology and Experimental Therapeutics, 338(1), 114-124. [CrossRef]
9. Ahn, K., Johnson, D.S., Mileni, M., Beidler, D., Long, J.Z., McKinney, M.K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., Lazerwith, S., Stiff, C., Kamtekar, S., Bhattacharya, K., Zhang, Y., Swaney, S., Van Becelaere, K., Stevens, R.C., Cravatt, B.F. (2009). Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chemistry & Biology, 16(4), 411-420. [CrossRef]
10. Rocha, J.F., Santos, A., Gama, H., Moser, P., Falcao, A., Pressman, P., Wallace Hayes, A., Soares-da-Silva, P. (2022). Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers. Clinical Pharmacology & Therapeutics, 111(2), 391-403. [CrossRef]
11. Tripathi, R.K.P. (2020). A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents. European Journal of Medicinal Chemistry, 188, 111953. [CrossRef]
12. Fazio, D., Criscuolo, E., Piccoli, A., Barboni, B., Fezza, F., Maccarrone, M. (2020). Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold? Expert Opinion on Drug Discovery, 15(7), 765-778. [CrossRef]
13. Shang, Y., Hao, Q., Jiang, K., He, M., Wang, J. (2020). Discovery of heterocyclic carbohydrazide derivatives as novel selective fatty acid amide hydrolase inhibitors: design, synthesis and anti-neuroinflammatory evaluation. Bioorganic Medicinal Chemistry Letters, 30(10), 127118. [CrossRef]
14. Jaiswal, S., Ayyannan, S.R. (2022). Discovery of Isatin-Based Carbohydrazones as Potential Dual Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase. ChemMedChem, 17(1), e202100559. [CrossRef]
15. Freitas, R., Barbosa, J.M.C., Bernardino, P., Sueth-Santiago, V., Wardell, S., Wardell, J.L., Decote-Ricardo, D., Melo, T. G., da Silva, E.F., Salomao, K., Fraga, C.A.M. (2020). Synthesis and trypanocidal activity of novel pyridinyl-1,3,4-thiadiazole derivatives. Biomedicine & Pharmacotherapy, 127, 110162. [CrossRef]
16. Fugard, A.J., Thompson, B.K., Slawin, A.M., Taylor, J.E., Smith, A.D. (2015). Organocatalytic Synthesis of Fused Bicyclic 2,3-Dihydro-1,3,4-oxadiazoles through an Intramolecular Cascade Cyclization. Organic Letters, 17(23), 5824-5827. [CrossRef]
17. Sarıgöl, D., Yüksel, D., Okay, G., Uzgören-Baran, A. (2015). Synthesis and structural studies of acyl hydrazone derivatives having tetrahydrocarbazole moiety. Journal of Molecular Structure, 1086, 146-152. [CrossRef]
18. Syakaev, V.V., Podyachev, S.N., Buzykin, B.I., Latypov, S.K., Habicher, W.D., Konovalov, A.I. (2006). NMR study of conformation and isomerization of aryl- and heteroarylaldehyde 4-tert-butylphenoxyacetylhydrazones. Journal of Molecular Structure, 788(1-3), 55-62. [CrossRef]
19. Alp, A.S., Kilcigil, G., Ozdamar, E.D., Coban, T., Eke, B. (2005). Synthesis and evaluation of antioxidant activities of novel 1,3,4-oxadiazole and imine containing 1H-benzimidazoles. Turkish Journal of Chemistry, 39, 42-53. [CrossRef]
20. Munir, R., Javid, N., Zia-Ur-Rehman, M., Zaheer, M., Huma, R., Roohi, A., Athar, M.M. (2021). Synthesis of Novel N-Acylhydrazones and Their C-N/N-N Bond Conformational Characterization by NMR Spectroscopy. Molecules, 26(16). [CrossRef]